Racura Oncology Reports First Patient Treated in RC220 Lung Cancer Trial and $34.3 Million Cash Reserve Extending Runway to 2028

RC220’s Mechanism Confirmed via c-MYC Silencing Data at AACR 2026

At the 2026 American Association for Cancer Research Annual Meeting in San Diego, Racura Oncology presented key preclinical data advancing understanding of RC220. Senior Scientist Dr Sumit Sahni revealed that (E,E)-bisantrene, the active pharmaceutical compound, silences c-MYC gene expression by binding and stabilizing G-quadruplex DNA structures in the c-MYC promoter. This mechanistic insight underpins Racura’s ongoing and future oncology clinical programs targeting diseases driven by c-MYC dysregulation.

Given that c-MYC is dysregulated in up to 70% of all cancers, RC220’s targeted mechanism addresses a significant patient population. This molecular targeting aligns with Racura’s strategic focus on acute myeloid leukemia, EGFR-mutated lung cancer, and anthracycline cardioprotection. Presenting this data at a premier oncology conference reinforces the scientific foundation of Racura’s development pipeline and its engagement with the global cancer research community.

HARNESS-1 Trial Marks First Patient Treatment with RC220-Osimertinib Combination

On 25 June 2026, Racura Oncology reached a pivotal milestone with the first patient treated in the Phase 1 HARNESS-1 trial evaluating RC220 alongside osimertinib for EGFR-mutated non-small cell lung cancer. Principal Investigator Associate Professor Surein Arulananda and his team at Monash Health, Clayton, Victoria, led the treatment, with no adverse events recorded during or after RC220 infusion, supporting the trial’s safety profile.

The HARNESS-1 trial expands Racura’s clinical strategy beyond monotherapy by combining RC220 with established oncology agents. On 3 July 2026, the Bellberry Human Research Ethics Committee approved the trial protocol, enabling additional Australian sites to participate. Following ethics approval, Chris O’Brien Lifehouse and Austin Health progressed through governance and site activation, enhancing patient recruitment and broadening evaluation of RC220-osimertinib in this commercially significant lung cancer subset.

CPACS Cardioprotection Trial Advances Dose Level After Positive Safety Review

In May 2026, the Phase 1 Cardioprotection and Anticancer Synergy (CPACS) trial achieved dose escalation to 80mg/m² of RC220 after safety and pharmacokinetic data review found no dose-limiting toxicities. This positive safety signal supports Racura’s clinical development plans. The CPACS trial spans Australia, Hong Kong, and South Korea, reflecting Racura’s expanding international clinical operations and regulatory engagement.

The CPACS trial targets cardioprotection in patients undergoing anthracycline chemotherapy, which is limited by cardiotoxicity risks. RC220’s development aims to mitigate these risks, potentially allowing higher or more frequent anthracycline dosing in solid tumor patients. The successful dose escalation without safety concerns validates ongoing trial progression and strengthens RC220’s therapeutic potential across oncology indications.

Capital Raises Totaling $26.2 Million Bolster Racura’s Financial Position in June Quarter

During the June quarter, Racura Oncology secured $26.2 million in funding, reflecting robust shareholder and institutional investor confidence. On 28 May 2026, a no-fee underwriting agreement with shareholder Dr AJ Robinson facilitated full conversion of $1.25 million in Piggyback Options, raising $25.2 million. Dr Robinson’s continued support follows his prior $3.22 million private placement in December 2025. Additionally, on 4 June 2026, a strategic private placement to a specialist institutional healthcare investor issued 526,315 shares at $1.90 each, raising $1 million.

Since 2025, Racura has raised $34.3 million through various mechanisms, including option conversions, private placements, and underwriting. These funds support RC220 clinical programs targeting acute myeloid leukemia, EGFR-mutated lung cancer, and anthracycline cardioprotection, while also providing general working capital. The addition of a specialist institutional investor underscores recognition of Racura’s clinical progress and market positioning within the healthcare investment sector.

$34.3 Million Cash Reserve Ensures Operational Runway Through 2028

As of 30 June 2026, Racura Oncology’s cash and equivalents stood at $34.3 million, providing substantial financial flexibility to advance clinical programs. The company anticipates this cash will fund all committed activities through calendar year 2028, offering operational certainty and reducing near-term financing risks for shareholders.

During the quarter, total expenditure of $2.45 million was recorded, with over 75% directed toward research, development, and drug manufacturing. This capital-efficient approach prioritizes clinical program advancement over corporate overhead, positioning Racura to execute its commercial strategy across multiple oncology indications while managing shareholder capital prudently during clinical development.

Racura’s RC220: Multi-Indication Development Strategy in Oncology and Cardioprotection

Headquartered in Sydney, Racura Oncology is focused on developing RC220, a therapeutic candidate with applications in oncology and cardioprotection. The company targets acute myeloid leukemia, EGFR-mutated non-small cell lung cancer, and anthracycline cardioprotection in solid tumor patients. RC220’s mechanism—silencing c-MYC gene expression via G-quadruplex stabilization—provides a scientific basis for its application across these indications where c-MYC dysregulation contributes to disease or treatment toxicity.

This multi-indication strategy reflects current oncology drug development trends, leveraging a single mechanism to address diverse therapeutic needs. By pursuing both cardioprotection and anti-cancer applications, Racura aims to broaden RC220’s patient reach and commercial potential. The CPACS trial’s three-country footprint and expanding Australian HARNESS-1 sites demonstrate operational capacity for international clinical trials and collaboration with leading academic centers, strengthening prospects for regulatory engagement and partnerships.

Corporate and Governance Strengthened by New Operations Leadership

Beyond clinical progress, Racura enhanced corporate governance by appointing Dr Suzanne McCusker as Corporate Operations Manager. Bringing extensive expertise in operations, governance, and business management, Dr McCusker has improved organisational planning and operational efficiency, supporting the company’s management of multi-site trials and international regulatory activities.

Additionally, Dr Feroz Ahmad and Prof Michael Kelso conducted supplier audits and explored clinical collaborations in China, underscoring Racura’s commitment to quality assurance in manufacturing partnerships. These efforts reinforce the company’s capability to reliably execute complex clinical programs across multiple jurisdictions.

Post-Quarter Engagement at Thoracic Oncology Group of Australasia Meeting

Following the quarter, from 15 to 17 July 2026, Dr Rodney Cusack and Dr Feroz Ahmad participated in the Thoracic Oncology Group of Australasia Annual Scientific Meeting in Melbourne. This event facilitated engagement with leading lung cancer clinicians, researchers, and industry stakeholders to discuss (E,E)-bisantrene and RC220 within the HARNESS-1 trial context, enhancing Racura’s profile in the Australian thoracic oncology community.

With HARNESS-1 in early patient recruitment, this interaction supports trial credibility and may aid investigator recruitment and site activation as the study expands beyond Monash Health. Racura’s focus on collaboration with thoracic oncology leaders positions the company for sustained clinical engagement throughout the trial duration.

Risks Associated with Racura’s Clinical Development and Market Position

Despite significant milestones, Racura faces inherent risks typical of clinical-stage biopharmaceutical development. The company’s therapeutic prospects rely heavily on RC220 and its precursor (E,E)-bisantrene, presenting concentration risk. Clinical trial outcomes remain uncertain, with potential adverse safety signals, efficacy shortfalls, or manufacturing challenges possibly delaying or halting development.

The early-phase HARNESS-1 and CPACS trials require positive interim data and regulatory approvals to progress, which are not guaranteed. Operating in competitive oncology and cardioprotection markets dominated by larger pharma, Racura’s success depends on protecting intellectual property, securing partnerships, and achieving sufficient patient recruitment. While the $34.3 million cash position supports operations through 2028, further capital or positive trial results enabling partnerships will be necessary for later-stage development. Regulatory pathways for novel oncology mechanisms are complex, and approval is uncertain across jurisdictions and indications.